Novo Nordisk’s downward guidance led to a 20% stock drop, with sales growth projections slashed due to competition in the obesity drug market. Outgoing CEO Lars Jøregensen cited compounding products and unexpected drug shortages as key issues affecting the company’s performance. Compounded products from Novo’s ex-partner Hims & Hers have contributed to Novo losing its first-to-market position, with competitor Eli Lilly lobbying Congress to enforce FDA rules against compounding. Incoming CEO Mike Doustdar acknowledges the disappointing stock decline but remains committed to steering the company back to growth.

Read more at Yahoo Finance: Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook